Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Heparin-induced thrombocytopenia.

¹Department of Medicine, St. George Clinical School, Sydney, NSW, Australia. beng.chong@unsw.edu.au

Journal of Thrombosis and Haemostasis : JTH

|July 23, 2003

Summary

Heparin-induced thrombocytopenia (HIT) is a serious adverse drug event causing thrombosis, not bleeding. Diagnosis requires clinical suspicion confirmed by lab tests, followed by heparin cessation and alternative anticoagulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk.

Journal of autoimmunity·2021

Same author

Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis.

International journal of laboratory hematology·2018

Same author

Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process.

Clinical & experimental metastasis·2015

Same author

Recommendations for the use of the non-obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug-induced thrombocytopenia: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2015

Same author

Beware of NK cells in pre-clinical metastasis models.

Clinical & experimental metastasis·2013

Same author

EGFR and the complexity of receptor crosstalk in the cardiovascular system.

Current molecular medicine·2012

Area of Science:

Pharmacology
Hematology
Immunology

Background:

Heparin-induced thrombocytopenia (HIT) is a common and serious adverse drug reaction.
Unlike other drug-induced thrombocytopenias, HIT primarily causes thrombosis, potentially leading to severe outcomes like limb gangrene or death.
The condition is immunologically mediated by antibodies targeting the platelet factor 4-heparin complex.

Purpose of the Study:

To outline the pathophysiology, diagnosis, and management of Heparin-induced thrombocytopenia (HIT).
To emphasize the importance of differentiating HIT from other thrombocytopenic conditions.
To provide guidance on laboratory confirmation and treatment strategies for HIT.

Main Methods:

Review of the immunological mechanisms underlying HIT, including antibody formation and platelet activation.
Discussion of diagnostic criteria, emphasizing clinical suspicion supported by laboratory tests (immunoassays and functional assays).
Description of management protocols, including immediate heparin cessation and initiation of alternative anticoagulants.

Main Results:

HIT involves antibody-PF4-heparin complexes binding to platelet receptors, causing activation and aggregation, leading to thrombosis.
Clinical diagnosis is crucial but requires laboratory confirmation, especially in complex cases.
Effective management involves prompt discontinuation of heparin and transition to alternative anticoagulants like danaparoid, r-hirudin, or argatroban.

Conclusions:

Heparin-induced thrombocytopenia is a critical condition characterized by thrombosis due to an immune response.
Accurate and timely diagnosis, combining clinical assessment with laboratory testing, is essential for patient outcomes.
Immediate cessation of heparin and initiation of alternative anticoagulation, followed by warfarin, are key components of HIT management.

Related Experiment Videos